Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
On August 13, Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Balyasny Asset Management Dmitry Balyasny | 1,350,015 | $8,923,599 | +1% | 0.01% |
| 2. | Vivo Capital Albert Cha And Frank Kung | 1,350,000 | $8,923,500 | 0.81% | |
| 3. | Partner Fund Management Christopher Medlock James | 1,210,661 | $8,002,469 | +124% | 0.69% |
| 4. | Great Point Partners Jeffrey Jay And David Kroin | 1,200,000 | $7,932,000 | 1.5% | |
| 5. | Rubric Capital Management David Rosen | 867,424 | $5,733,673 | +26% | 0.05% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 79,704 | $561,264 | 0% | |
| 2. | 53,010 | $482,391 | 0% | |
| 3. | 16,000 | $132,880 | 0.01% | |
| 4. | 11,927 | $106,389 | 0% | |
| 5. | 11,000 | $100,100 | 0% |
News See All
9 Best Up and Coming Canadian Stocks to Buy
In this article, we will look at the 9 Best Up and Coming Canadian Stocks to Buy. On November 19, IG Wealth Management released its 2026 Market Outlook for Canada.
Hedge Fund Resource Center